ArticleFrontiers in cardiovascular medicine2025
Risk factors for thoracic aortic aneurysm and dissection among diabetic patients: a nationwide population-based study.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Diabetes mellitus (DM) has been reported to be associated with decreased risk for thoracic aortic aneurysm and dissection (TAAD). However, risk factors for TAAD in diabetic patients remain undetermined. This study aims to investigate diabetes-specific risk factors for TAAD development in diabetic patients. Methods: This population-based study utilized the National Health Insurance Service database in Republic of Korea. We followed 2,328,347 type 2 DM patients undergoing health check-ups from 2009 to 2012 until new TAAD diagnosis, death, or December 31, 2019. Cox proportional-hazards regression models were used to identify risk factors for TAAD development. Results: TAAD was newly diagnosed in 0.02% (4,512/2,328,347) of patients. In the fully-adjusted model incorporating baseline characteristics and antidiabetic medications, the risk for TAAD was increased with age (HR: 1.05, 95% CI: 1.05-1.06) and males (HR: 1.37, 95% CI: 1.26-1.49). Meanwhile, the risk of TAAD was decreased in patients with a longer diabetes duration (HR: 0.97, 95% CI: 0.96-0.99) and metformin use (HR: 0.91 95% CI: 0.85-0.97). Conclusions: Our study findings suggest that longer diabetes duration and metformin may reduce TAAD risk. Additional research is needed to investigate whether changes in glucose control and treatment strategies can decrease the development of TAAD in diabetic patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.